Avastin
Drug Name | Form | Strength | Formulary Unrestricted | Formulary Restricted | Non-Formulary | Interchange |
---|---|---|---|---|---|---|
Avastin | SOLUTION, INTRAVENOUS | 25 mg/mL | ||||
Alymsys | SOLUTION, INTRAVENOUS | 100 mg/4 mL, 400 mg/16 mL | ||||
Avzivi | SOLUTION, INTRAVENOUS | 100 mg/4 mL, 400 mg/16 mL | ||||
Mvasi | SOLUTION, INTRAVENOUS | 100 mg/4 mL, 400 mg/16 mL | ||||
Zirabev | SOLUTION, INTRAVENOUS | 100 mg/4 mL, 400 mg/16 mL |
For Updated Formulary Preferred Products (Inpatient and Outpatient): Preferred Products for Select Agents
Drug reviewed for Outpatient Infusion (updated May 7, 2021)
Doses for intravitreal use (off-label for macular degeneration and retinopathy of prematurity) are prepared in the IV room.
Avastin inpatient use is approved for retinopathy of prematurity in neonate: Formula Sheet: AVASTIN for intravitreal use in retinopathy of prematurity
Avastin is approved for use in macular degeneration in outpatient setting.
Alymsys, Avzivi, Mvasi & Zirabev will currently not be used for retinopathy of prematurity (ROP) or macular degeneration.
For oncology cases, Alymsys, Avastin, Avzivi, Mvasi, & Zirabev are limited to outpatient cases only. Substitution will be determined by cost/reimbursement of patient case and/or economics at a specific time period for oncology indications
Outpatient Bevacizumab cycle 2+ Rapid infusion protocol available for adults. Outpatient Bevacizumab cycle 2+ Rapid infusion protocol (Adult)
Reviewed: June 22, 2005 (Oncology), 24 April 2018 (Mvasi), 28 January 2020 (Zirabev), Sept 2022 (Alymsys), February 2024 (Avzivi)
Updated: October 25, 2006 (Macular Degeneration), May 10, 2011 (Retinopathy of Prematurity, Pediatric Subcommittee), and October 22, 2019 (Rapid Infusion)
Bevacizumab-maly (Alymsys)
Bevacizumab-tnjn (Avzivi) February 27, 2024